Evolus, Inc.

EOLS Nasdaq SEC CIK 1570562
Follow Evolus Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $78M +13% vs same quarter last year
Net income −$12.5M +20.5% vs same quarter last year
EPS, diluted −$0.19 +20.8% vs same quarter last year
Operating cash flow −$1.9M +86.8% vs same quarter last year
Revenue by quarter
$78.9M
$68.5M
$69.4M
$69M
$90.3M
$73.1M
$84.1M
$78M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$200M$0$200M$400MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$297.2M−$51.6M
FY24$266.3M−$50.4M
FY23$202.1M−$61.7M
FY22$148.6M−$74.4M
FY21$99.7M−$46.8M
FY20$56.5M−$163M
FY19$34.9M−$90M
FY18$0−$46.9M
FY17-−$4.5M
FY16--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−300%−200%−100%0%100%FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2566.3%−11%−17.4%
FY2468.5%−12.9%−18.9%
FY2368.1%−24.4%−30.5%
FY2260.4%−44%−50.1%
FY2156.3%−44.6%−47%
FY2067.6%−270.7%−288.3%
FY1977.1%−283.3%−257.8%
FY18---
FY17---
FY16---
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$45.7M
FY24−$19.5M
FY23−$34.5M
FY22−$86.5M
FY21−$33.8M
FY20−$58.7M
FY19−$93.7M
FY18−$25.7M
FY17−$13.2M
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Evolus
  • Healthcare median
−300%−200%−100%0%FY17FY19FY21FY23FY25
Show the numbers
YearEvolusHealthcare median
FY25−17.4%−30.6%
FY24−18.9%−47%
FY23−30.5%−58%
FY22−50.1%−80.4%
FY21−47%−71.8%
FY20−288.3%−62.2%
FY19−257.8%−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%